{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 443996139
| IUPAC_name = 1-[(2''R'',3''S'',4''R'',5''R'')-3-Fluoro-4-hydroxy-5-(hydroxymethyl)- 2-tetrahydrofuranyl]-5-iodopyrimidine-2,4-dione
| image = Fialuridine.png
| alt = Skeletal formula
| image2 = Fialuridine-3D-balls.png
| alt2 = Ball-and-stick model
<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number =  69123-98-4
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 50313
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 53T7IN77LC
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04181
| NIAID_ChemDB = 070971
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 271475
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 45627

<!--Chemical data-->
| C=9 | H=10 | F=1 | I=1 | N=2 | O=5 
| molecular_weight = 372.09 g/mol
| synonyms = 2′-Fluoro-5-iodouracil
| smiles            = c1c(c(=O)[nH]c(=O)n1[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)F)I
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C9H10FIN2O5/c10-5-6(15)4(2-14)18-8(5)13-1-3(11)7(16)12-9(13)17/h1,4-6,8,14-15H,2H2,(H,12,16,17)/t4-,5+,6-,8-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = IPVFGAYTKQKGBM-BYPJNBLXSA-N
}}
'''Fialuridine''', or 1-(2-deoxy-2-fluoro-1-<small>D</small>-arabinofuranosyl)-5-iodouracil (FIAU), is a [[nucleoside analogue]] that was investigated as a potential therapy for [[hepatitis B virus]] infection. In a 1993 clinical study at the [[NIH]], unexpected toxicity led to the death of 5 out of 15 patients from [[liver failure]] associated with [[lactic acidosis]]; two further participants required [[liver transplantation]]. This toxicity was unusual in that it was not predicted by animal studies. It is suspected that the drug's toxicity was due to its damaging [[mitochondrial toxicity|mitochondria]].<ref>Tujios S, Fontana RJ. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol. 2011 Apr;8(4):202-11. Review. {{PMID|21386809}}</ref><ref>{{cite journal |author=McKenzie R |title=Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B |journal=N. Engl. J. Med. |volume=333 |issue=17 |pages=1099–1105 |year=1995 |pmid=7565947 |doi=10.1056/NEJM199510263331702 |name-list-format=vanc|author2=Fried MW |author3=Sallie R |display-authors=3 |last4=Conjeevaram |first4=Hari |last5=Di Bisceglie |first5=Adrian M. |last6=Park |first6=Yoon |last7=Savarese |first7=Barbara |last8=Kleiner |first8=David |last9=Tsokos |first9=Maria}}</ref><Ref>{{cite journal|last=Thomson|first=Larry|title=The Cure that Killed|journal=Discover|date=1 March 1994|url=http://discovermagazine.com/1994/mar/thecurethatkille345#.UnVB6ErVlkd|accessdate=2 November 2013}}</ref>

== References ==
{{Reflist}}

[[Category:Antivirals]]
[[Category:Nucleosides]]
[[Category:Organofluorides]]
[[Category:Organoiodides]]
[[Category:Tetrahydrofurans]]
[[Category:Alcohols]]
[[Category:Pyrimidinediones]]
[[Category:Arabinosides]]
[[Category:Clinical trial disasters]]
{{antiinfective-drug-stub}}